NEW YORK (TheStreet) -- Exact Sciences (EXAS - Get Report) shares have pulled back in the past month due to a secondary offering and profit taking after a huge run-up. If the Preventive Services Task Force gives the company's Cologuard cancer screening product a high rating, however, the stock will take off, said Garvin Jabusch, chief investment officer for Green Alpha Advisors.
"It's already being used at the Mayo Clinic, they are obviously leaders in cancer prevention," said Jabusch. "They are also working on a non-invasive, just breathe into it, lung cancer screening so I do think there is reason to be cautious but the pullback could provide a really nice entry level should they get a favorable rating this year."
Shares of Exact Sciences have fallen 18% in the past month, but are up 60% in the past 12 months. The medical laboratories and research company priced a 7-million share secondary offering on Tuesday at $25.50 a share, which pulled the stock down over 6%. The company said it plans to use the net proceeds from the offering to fund the expansion of its Cologuard commercialization and product development efforts, as well as for general corporate and working capital purposes.
Jabusch and his climate friendly fund also own shares of Google (GOOG - Get Report), which is having a strong month after it posted Street-beating earnings last week. Google said last week second quarter revenue excluding traffic acquisition costs (ex-TAC) came in at $14.35 billion and adjusted earnings a share was $6.99. Wall Street analysts expected the company to earn $6.70 a share on ex-TAC revenue of $14.27 billion.
Google shares have risen 22% in the past four weeks and Jabusch expects more good things to come from the company's R&D labs.
"They are the best ad-serving machine in the world. 90% of their revenue comes from their ad-serving but it's not always going to be that way," said Jabusch. "Not because ads are going to slip so much. But because one or two or more of these moon shots are going to take off and become huge for Google."
Finally, Jabusch is positive on Trina Solar (TSL), down 27% in the past month, and Canadian Solar (CSIQ - Get Report), down 20% in the past month, despite the pair of solar companies struggling in the face of anti-dumping tariffs in the U.S. on top of other company specific woes.
"I think you will see the better solar companies with lower amounts of debt, better distribution channels and are the most geographically diversified do very well over the long run," said the contrarian Jabusch.